BioSpace News Archive

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the dosing of the first patients in HBV003.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022.

Instil Bio, Inc. today announced that it has voluntarily paused enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 and has

Inozyme Pharma, Inc. (Nasdaq: INZY) today announced the publication of an article titled, “ENPP1 Deficiency: A clinical update on the relevance of individual variants using a locus-specific database,” in Human Mutation.

Rakovina Therapeutics Inc. is pleased to announce the presentation of new data during the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, which was held in Barcelona Spain October 26-28, 2022.

Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full year results for the twelve months ended 30 June 2022.

Fianostics GmbH in Austria has launched new COVID-19 antibody test kits that include Mitra® devices from Neoteryx, the microsampling brand of Trajan Scientific and Medical.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today it has received CE marking for their BiWaze® Cough system in accordance with European Union’s Medical Device Regulation (MDR) 2017/745.

Noul Co., Ltd., a Biotech Company, announced that it will participate in the 2022 American Society of Tropical Medicine and Hygiene annual meeting held from October 30 to November 3 in Seattle, USA.

Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases.